Strs Ohio Has $239,000 Stake in Celcuity, Inc. $CELC

Strs Ohio lowered its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 71.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,400 shares of the company’s stock after selling 6,000 shares during the period. Strs Ohio’s holdings in Celcuity were worth $239,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of CELC. Creative Planning bought a new stake in shares of Celcuity in the 2nd quarter valued at about $177,000. Rhumbline Advisers grew its holdings in Celcuity by 1.2% during the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the period. XTX Topco Ltd acquired a new position in Celcuity during the second quarter valued at approximately $169,000. Quantinno Capital Management LP increased its stake in Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock valued at $3,245,000 after purchasing an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co increased its stake in Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after purchasing an additional 60,849 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Celcuity news, Director David Dalvey sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This trade represents a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock worth $5,111,950 in the last quarter. 13.33% of the stock is currently owned by corporate insiders.

Celcuity Price Performance

NASDAQ CELC opened at $125.64 on Tuesday. The firm’s 50 day moving average is $117.22 and its 200-day moving average is $105.30. The company has a quick ratio of 10.55, a current ratio of 10.55 and a debt-to-equity ratio of 3.20. The company has a market capitalization of $6.07 billion, a PE ratio of -33.15 and a beta of 0.09. Celcuity, Inc. has a 12-month low of $9.51 and a 12-month high of $151.02.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.09. Equities research analysts anticipate that Celcuity, Inc. will post -3.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CELC has been the topic of a number of recent analyst reports. Guggenheim lifted their price target on shares of Celcuity from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Monday, April 20th. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Needham & Company LLC lifted their target price on Celcuity from $122.00 to $157.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Finally, Craig Hallum reissued a “buy” rating and issued a $189.00 target price on shares of Celcuity in a research note on Monday, May 4th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Celcuity currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.50.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.